N

NuVasive Inc
F:NK8

Watchlist Manager
NuVasive Inc
F:NK8
Watchlist
Price: 36.8 EUR Market Closed
Market Cap: €1.9B

NuVasive Inc
Cash from Financing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

NuVasive Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
N
NuVasive Inc
F:NK8
Cash from Financing Activities
-$130.6m
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
-3%
Boston Scientific Corp
NYSE:BSX
Cash from Financing Activities
-$395m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Edwards Lifesciences Corp
NYSE:EW
Cash from Financing Activities
-$956.8m
CAGR 3-Years
15%
CAGR 5-Years
-14%
CAGR 10-Years
-20%
Stryker Corp
NYSE:SYK
Cash from Financing Activities
$113m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Cash from Financing Activities
-$6.3B
CAGR 3-Years
-6%
CAGR 5-Years
-16%
CAGR 10-Years
-7%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash from Financing Activities
-$2.4B
CAGR 3-Years
3%
CAGR 5-Years
-94%
CAGR 10-Years
N/A
No Stocks Found

NuVasive Inc
Glance View

Market Cap
1.9B EUR
Industry
Health Care

In the ever-evolving world of healthcare innovation, NuVasive Inc. stands as a noteworthy beacon in the field of spinal surgery technology. Founded in 1997 and based in San Diego, California, the company has carved a niche for itself with its minimally invasive surgical procedures designed to transform spinal care. The cornerstone of its success lies in its proprietary Maximum Access Surgery (MAS) platform, which reduces operating time and recovery periods for patients undergoing spinal procedures. By integrating its cutting-edge surgical solutions with advanced neuromonitoring technology and a comprehensive suite of procedural systems, NuVasive aids surgeons in executing complex operations with precision and efficiency. This unique amalgamation of technology and medical expertise not only enhances surgical outcomes but also has cemented NuVasive’s reputation as a leader in less-invasive spinal surgery. Financially, NuVasive harnesses an effective business model that generates revenue through the sale of its specialized surgical equipment, including implants and biologics, as well as through service offerings like its intraoperative monitoring services. The company's revenue streams are largely driven by product sales directly to hospitals and surgical centers, where innovative tools and technologies are in high demand. As healthcare facilities increasingly seek advanced methods to improve patient outcomes and operating efficiencies, NuVasive finds itself at the forefront of this demand, continuously expanding its product portfolio and global reach. By investing heavily in research and development, the company ensures its products stay at the cutting edge of medical technology, providing not just immediate financial growth, but also a long-term strategic advantage in the global market for spinal surgery solutions.

NK8 Intrinsic Value
Not Available
N

See Also

What is NuVasive Inc's Cash from Financing Activities?
Cash from Financing Activities
-130.6m USD

Based on the financial report for Jun 30, 2023, NuVasive Inc's Cash from Financing Activities amounts to -130.6m USD.

What is NuVasive Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-3%

Over the last year, the Cash from Financing Activities growth was -1 239%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett